Procedure for Emergency Requests of Cytogam^®

First, we ask that always attempt to order through your distributor before making any special emergency requests. Distributors do receive a weekly allocation of Cytogam^® , and remain the fastest means by which to procure product. Additionally, the emergency stock of product is limited, and finite.
If upon ordering through your distributor, you are unable to procure adequate product to meet your imminent patient needs, the prescribing physician should fax (610-878-4888) a “letter of medical request” to the Medical Affairs Department (attn. Dr. Garrett Bergman, Medical Director) here at CSL Behring. Within the letter please include:
- The specific “de-identified” (patient initials only) patient request, including patient weight and age and the condition for which Cytogam is being used.
- Number of Cytogam vials that you are requesting (note: requests should be limited to a 2-week supply)
- Prescribing physician contact info, including direct-office or pager number
- Pharmacist contact info
- The name and location of your usual Cytogam distributor
If the request is approved, the physician will be notified and a drop-shipment will be arranged with your usual distributor, and the hospital pharmacist
If the request is denied, the prescribing physician will be notified.

Once again we apologize for any inconvenience caused by the tight supply of Cytogam^® , and we continue to work to improve the quantity and consistency of product supply. However, until such time that Cytogam^® supply improves, we believe that the process stated above best serves the needs of all our patients throughout the country.

© 2008 CSL Behring

Important Safety Information

Cytogam^® is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart.

Cytogam^® is contraindicated in individuals with a history of a prior severe reaction associated with the administration of this or other human immunoglobulin preparations and in persons with selective immunoglobulin A deficiency who have known antibodies to IgA.

Immune Globulin Intravenous (Human) products have been reported to be associated with renal dysfunction, acute renal failure, osmotic nephrosis and death. Patients predisposed to acute renal failure include patients with any degree of preexisting renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia or patients receiving known nephrotoxic drugs. Especially in such patients, IGIV products should be administered at the minimum concentrations available and the minimum rate of infusion practicable.

Increases in serum creatinine and blood urea nitrogen (BUN) have been observed as soon as one to two days following IGIV infusion. Progression to oliguria or anuria requiring dialysis has been observed.

Cytogam^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Minor reactions, such as flushing, chills, muscle cramps, back pain, fever, nausea, vomiting, arthralgia, and wheezing, were the most frequent adverse reactions observed during the clinical trials for Cytogam^®.

For more information about Cytogam^®, please see the full prescribing information.

Cytogam^® is a registered trademark of CSL Behring AG.

Procedure for Emergency Requests of Cytogam®

© 2008 CSL Behring

Important Safety Information

Procedure for Emergency Requests of Cytogam^®